JP2009515823A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515823A5
JP2009515823A5 JP2008535681A JP2008535681A JP2009515823A5 JP 2009515823 A5 JP2009515823 A5 JP 2009515823A5 JP 2008535681 A JP2008535681 A JP 2008535681A JP 2008535681 A JP2008535681 A JP 2008535681A JP 2009515823 A5 JP2009515823 A5 JP 2009515823A5
Authority
JP
Japan
Prior art keywords
nucleotide
tlr
oligonucleotide
composition
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008535681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515823A (ja
JP6406793B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/039954 external-priority patent/WO2007047396A2/en
Publication of JP2009515823A publication Critical patent/JP2009515823A/ja
Publication of JP2009515823A5 publication Critical patent/JP2009515823A5/ja
Application granted granted Critical
Publication of JP6406793B2 publication Critical patent/JP6406793B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008535681A 2005-10-12 2006-10-12 トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物 Expired - Fee Related JP6406793B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US72603405P 2005-10-12 2005-10-12
US60/726,034 2005-10-12
US78424306P 2006-03-21 2006-03-21
US60/784,243 2006-03-21
US82544006P 2006-09-13 2006-09-13
US60/825,440 2006-09-13
PCT/US2006/039954 WO2007047396A2 (en) 2005-10-12 2006-10-12 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

Publications (3)

Publication Number Publication Date
JP2009515823A JP2009515823A (ja) 2009-04-16
JP2009515823A5 true JP2009515823A5 (enExample) 2018-08-30
JP6406793B2 JP6406793B2 (ja) 2018-10-17

Family

ID=37963095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535681A Expired - Fee Related JP6406793B2 (ja) 2005-10-12 2006-10-12 トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物

Country Status (9)

Country Link
US (4) US8357665B2 (enExample)
EP (4) EP2341059A1 (enExample)
JP (1) JP6406793B2 (enExample)
KR (1) KR101455081B1 (enExample)
CN (2) CN101287742B (enExample)
AU (1) AU2006304205C1 (enExample)
CA (1) CA2624755C (enExample)
ES (2) ES2542989T3 (enExample)
WO (1) WO2007047396A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102604957B (zh) * 2003-06-11 2015-10-07 艾德拉药物股份有限公司 稳定的免疫调节寡核苷酸
EP2341059A1 (en) 2005-10-12 2011-07-06 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2446903B1 (en) 2006-11-20 2019-10-09 President and Fellows of Harvard College Compositions for treating itch
JP5563455B2 (ja) * 2007-08-01 2014-07-30 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の新規な合成アゴニスト
KR20100066512A (ko) * 2007-08-15 2010-06-17 이데라 파마슈티칼즈, 인코포레이티드 톨 유사 수용체 조절자
CN102083984A (zh) * 2007-12-26 2011-06-01 森托科尔奥索生物科技公司 食蟹猴Toll样受体3
WO2009154610A1 (en) * 2008-06-17 2009-12-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
CN101643496B (zh) * 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
EP2356216B1 (en) * 2008-10-03 2016-06-01 Janssen Biotech, Inc. Papio cynocephalus toll-like receptor 3
CN102281880A (zh) * 2008-10-06 2011-12-14 艾德拉药物股份有限公司 类Toll受体抑制剂在高胆固醇血症和高脂血症及相关疾病的预防和治疗中的用途
CA2742531A1 (en) 2008-11-04 2010-05-14 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 5 expression by antisense oligonucleotides
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
RU2011135993A (ru) * 2009-01-30 2013-03-10 Идера Фармасьютикалз, Инк. Новые синтетические агонисты tlr9
ES2534947T3 (es) 2009-03-25 2015-04-30 The Board Of Regents Of The University Of Texas System Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
CA2762206C (en) * 2009-06-01 2017-06-27 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
WO2011005942A2 (en) * 2009-07-08 2011-01-13 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
US20120172429A1 (en) 2009-07-10 2012-07-05 Woolf Clifford J Permanently charged sodium and calcium channel blockers as anti- inflammatory agents
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
HRP20150566T1 (hr) * 2009-08-27 2015-07-17 Idera Pharmaceuticals, Inc. Kompozicija za inhibiciju ekspresije gena i njegova upotreba
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EP3213770B1 (en) * 2010-11-19 2021-02-24 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
WO2014110081A1 (en) * 2013-01-08 2014-07-17 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US9688993B2 (en) 2015-02-13 2017-06-27 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
CN104807994B (zh) * 2015-04-29 2016-08-24 大连理工大学 一种基于脱碱基位点的免标记凝血酶检测方法
KR101745520B1 (ko) * 2015-05-29 2017-06-12 아주대학교산학협력단 신규한 tlr4 길항제
US11021443B2 (en) 2015-08-03 2021-06-01 President And Fellows Of Harvard College Charged ion channel blockers and methods for use
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
CN114807152A (zh) 2016-06-08 2022-07-29 哈佛学院院长及董事 工程化病毒载体减少了炎症和免疫反应的诱导
WO2018095697A1 (en) 2016-11-23 2018-05-31 Berlin Cures Holding Ag Aptamers for use in inhibition and/or suppression of tlr9 activation
EP3690030A4 (en) 2017-09-28 2021-06-23 Industry-Academic Cooperation Foundation, Yonsei University METHOD FOR MANUFACTURING MYELOID-DERIVED SUPPRESSOR CELLS, SUPPRESSOR CELLS MANUFACTURED FROM MYEOLID AND USES THEREOF
EP3707262A1 (en) 2017-11-08 2020-09-16 President and Fellows of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
JP7692834B2 (ja) 2019-03-11 2025-06-16 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MA55320A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation
CA3129111A1 (en) 2019-03-11 2020-09-17 Bridget M. Cole Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3939987A4 (en) * 2019-03-13 2023-02-08 Cartiprime Co., Ltd. OLIGONUCLEOTIDE WITH ANTI-INFLAMMATORY ACTIVITY
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4118070A4 (en) 2020-03-11 2024-04-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
CA3202133A1 (en) * 2020-12-16 2022-06-23 Martin Gohlke Method for quantifying cpg-containing oligonucleotides in formulations comprising alum
WO2024137496A1 (en) 2022-12-19 2024-06-27 Six Therapeutics Inc. Compositions and methods of using cpg oligonucleotides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US97719A (en) * 1869-12-07 E-benez ee sperry
US239733A (en) * 1881-04-05 William w
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
JP5268214B2 (ja) * 1999-08-13 2013-08-21 イデラ ファーマシューティカルズ インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調
US6899891B2 (en) 1999-12-16 2005-05-31 Harry J. Siskind Nutritional composition, methods of producing said composition and methods of using said composition
AU783687B2 (en) 2000-01-26 2005-11-24 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP2003531915A (ja) * 2000-05-01 2003-10-28 ハイブリドン・インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
SE0201701D0 (sv) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003243409A1 (en) * 2002-06-05 2003-12-22 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
EP1393745A1 (en) * 2002-07-29 2004-03-03 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
CA2526212C (en) * 2003-05-16 2013-08-27 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
EA200600069A1 (ru) * 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
AU2005282889B2 (en) 2004-09-01 2012-03-15 Dynavax Technologies Corporation Methods and conpositions for inhibition of innate immune responses and autoimmunity
EP1819364A4 (en) 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
CA2591582A1 (en) 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
JP2009510096A (ja) 2005-09-27 2009-03-12 コーリー ファーマシューティカル ゲーエムベーハー アダプターオリゴヌクレオチドを用いたｔｌｒ媒介免疫応答の調節
US8383598B2 (en) 2005-10-12 2013-02-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8426375B2 (en) 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8399423B2 (en) 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2341059A1 (en) 2005-10-12 2011-07-06 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
KR20100066512A (ko) 2007-08-15 2010-06-17 이데라 파마슈티칼즈, 인코포레이티드 톨 유사 수용체 조절자
CA2703931C (en) 2007-10-26 2016-08-16 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production

Similar Documents

Publication Publication Date Title
JP2009515823A5 (enExample)
CN106535876B (zh) 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
JP6406793B2 (ja) トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物
US10144933B2 (en) Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US9617547B2 (en) Chiral nucleic acid adjuvant
JP4942646B2 (ja) 免疫賦活オリゴヌクレオチドマルチマー
US20070202575A1 (en) Oligodeoxynucleotide and its use to induce an immune response
JP7419268B2 (ja) 変異ｋｒａｓ配列及び脂質を含む化合物並びにその使用
EP3758712B1 (en) Cpg amphiphiles and uses thereof
US20060094680A1 (en) Immunostimulatory oligonucleotide multimers
US9260719B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
MX2011001317A (es) Modulacion de la expresion del receptor de tipo toll 3 por medio de oligonucleotidos antisentido.
US20070093439A1 (en) Short immunomodulatory oligonucleotides
WO2018048888A1 (en) Pd-1 specific aptamers
MX2011001315A (es) Modulacion de la expresion de los receptores del tipo toll 7 mediante oligonucleotidos antisentido.
TW202449155A (zh) 用於肌肉萎縮症之外顯子跳躍寡聚物
HK40045177B (en) Cpg amphiphiles and uses thereof
HK40045177A (en) Cpg amphiphiles and uses thereof
HK40043266A (en) Cpg amphiphiles and uses thereof
CN101426370A (zh) 免疫刺激性寡核苷酸多聚体